LTI Stock Overview
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Aptose Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.12 |
| 52 Week High | CA$7.38 |
| 52 Week Low | CA$1.12 |
| Beta | 1.42 |
| 1 Month Change | -16.42% |
| 3 Month Change | -34.88% |
| 1 Year Change | -81.24% |
| 3 Year Change | -98.33% |
| 5 Year Change | -95.65% |
| Change since IPO | -98.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| LTI | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.4% | -1.2% | 1.7% |
| 1Y | -81.2% | -23.0% | 2.3% |
Price Volatility
| LTI volatility | |
|---|---|
| LTI Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 36 | William Rice | www.aptose.com |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company’s clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin’s lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd.
Aptose Biosciences Inc. Fundamentals Summary
| LTI fundamental statistics | |
|---|---|
| Market cap | €17.80m |
| Earnings (TTM) | -€47.74m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs LTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LTI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$51.21m |
| Earnings | -US$51.21m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.26 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LTI perform over the long term?
See historical performance and comparison